Previous 10 | Next 10 |
home / stock / alpmy / alpmy news
2023-08-07 13:54:42 ET More on Apellis Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade) Apellis Pharmaceuticals: Biotech's Rising Star In C3 Inhibition Space Apellis extends selloff as JPMorgan becomes latest to downgrade Apellis off ...
2023-08-07 11:25:39 ET More on Poseida Poseida Therapeutics: Pioneering Cell And Gene Therapies Spark Excitement And Caution Poseida gains on FDA nod to start trials for CAR-T therapy Poseida stock falls ~8% postmarket after founder, executive chairman to step down ...
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy PR Newswire Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products u...
2023-08-06 22:42:08 ET Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Conference Call August 01, 2023, 04:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representative Director, President and CEO Yoshitsugu S...
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy PR Newswire IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at th...
China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab PR Newswire TOKYO , July 31, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced...
2023-07-21 19:02:28 ET Summary Merck & Co., Inc. has increased reliance on Keytruda and Gardasil. Merck became a Seeking Alpha Quant system Strong Buy on July 11 for no clear reason. Clinical catalysts have so far not moved Merck stock upward. Our previous cove...
Astellas and Eko Health Announce Agreement to Incorporate Next Generation Eko CORE 500™ Digital Stethoscope into Z1608, an Innovative Solution Under Development for Heart Failure Patients Built on Welldoc's Proven Digital Therapeutic Platform PR Newswire TOKYO , E...
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab PR Newswire TOKYO , July 13, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced the European Med...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy PR Newswire - Collaborative Research on Innovative Cartilage Organoid Cell Therapy for In...
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE PR Newswire If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction canc...
Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies PR Newswire - Focuses on digitizing cell manufacturing processes through robotics technology TOKYO ,...